{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:39:13Z","timestamp":1781793553951,"version":"3.54.5"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The prevalence of extended-spectrum beta-lactamase producing \u0395nterobacteriaceae (ESBL-PE) is increasing globally. ESBL-PE are an important cause of urinary tract infections (UTIs) in children. We aimed to characterize the clinical presentation, treatment and outcomes of childhood UTI caused by ESBL-PE in Europe.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Multicenter retrospective cohort study. Children 0 to 18 years of age with fever, positive urinalysis and positive urine culture for an ESBL-PE uropathogen, seen in a participating hospital from January 2016 to July 2017, were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main Outcome Measures:<\/jats:title>\n            <jats:p>Primary outcome measure: day of defervescence was compared between (1) initial microbiologically effective treatment (IET) versus initial microbiologically ineffective treatment (IIT) and (2) single initial antibiotic treatment versus combined initial antibiotic treatment. Secondary outcome measures: Clinical and microbiologic failure of initial treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We included 142 children from 14 hospitals in 8 countries. Sixty-one children had IET and 77 IIT. There was no statistical difference in time to defervescence for effective\/ineffective groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.722) and single\/combination therapy groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.574). Two of 59 (3.4%) and 4\/66 (6.1%) patients exhibited clinical failure during treatment (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.683) when receiving IET or IIT, respectively. Eight of 51 (15.7%) receiving IET and 6\/58 (10.3%) receiving IIT patients (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.568) had recurring symptoms\/signs suggestive of a UTI. Recurrence of a UTI occurred 15.5 days (interquartile range, 9.0\u201319.0) after the end of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Time to defervescence and clinical failure did not differ between IET\/IIT groups. Non-carbapenem beta-lactam antibiotics may be used for the empiric treatment of ESBL febrile UTIs, until susceptibility testing results become available.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002838","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T21:05:48Z","timestamp":1600463148000},"page":"1081-1087","source":"Crossref","is-referenced-by-count":8,"title":["Treatment and Outcomes of Children With Febrile Urinary Tract Infection Due to Extended Spectrum Beta-lactamase-producing Bacteria in Europe"],"prefix":"10.1097","volume":"39","author":[{"given":"Konstantinos","family":"Vazouras","sequence":"first","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George\u2019s University of London, London, United Kingdom"},{"name":"Stavros Niarchos Foundation-Collaborative Center for Clinical Epidemiology and Outcomes Research and Division of Infectious Diseases (CLEO), Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfen","family":"Hsia","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George\u2019s University of London, London, United Kingdom"},{"name":"School of Pharmacy, Queen\u2019s University Belfast, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Folgori","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George\u2019s University of London, London, United Kingdom"},{"name":"Paediatric Infectious Disease Unit, Department of Paediatrics, Luigi Sacco Hospital, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bielicki","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George\u2019s University of London, London, United Kingdom"},{"name":"Paediatric Pharmacology, University Children\u2019s Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Aguadisch","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie-Urgences, H\u00f4pital Louis-Mourier, Assistance Publique \u2013 H\u00f4pitaux de Paris, F-92700 Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Bamford","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Brett","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Urg\u00eancia e Unidade de Infecciologia, Hospital Pedi\u00e1trico, Centro Hospitalar e Universit\u00e1rio de Coimbra, Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Caseris","sequence":"additional","affiliation":[{"name":"Service p\u00e9diatrie g\u00e9n\u00e9rale, H\u00f4pital Robert Debr\u00e9, F-75019 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimante","family":"Cerkauskiene","sequence":"additional","affiliation":[{"name":"Clinic of Paediatrics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"De Luca","sequence":"additional","affiliation":[{"name":"Immunology and Infectious Diseases Unit, University Hospital Pediatric Department, Bambino Ges\u00f9 Children\u2019s Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"Third Department of Pediatrics, Aristotle University, Medical Faculty, School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kopsidas","sequence":"additional","affiliation":[{"name":"Stavros Niarchos Foundation-Collaborative Center for Clinical Epidemiology and Outcomes Research and Division of Infectious Diseases (CLEO), Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Manzanares","sequence":"additional","affiliation":[{"name":"Hospital 12 de Octubre, Facultad de Medicina, Universidad Complutense, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Planche","sequence":"additional","affiliation":[{"name":"Medical Microbiology Department, South West London Pathology, Jenner Wing St George\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Riordan","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases and Immunology, Alder Hey Children\u2019s NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Plankar","family":"Srovin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Valdivielso Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Regional University Hospital of Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Vergadi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Heraklion University Hospital, University of Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George\u2019s University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Basmaci","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie-Urgences, H\u00f4pital Louis-Mourier, Assistance Publique \u2013 H\u00f4pitaux de Paris, F-92700 Colombes, France"},{"name":"Universit\u00e9 de Paris, Infection, Antimicrobiens, Mod\u00e9lisation, Evolution, Unit\u00e9 Mixte de Recherche 1137, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update.","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.12688\/f1000research.14822.1","article-title":"Treatment of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?.","volume":"7","author":"Pana","year":"2018","journal-title":"F1000Research"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"Treatment of multidrug-resistant Gram-negative infections in children.","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diagmicrobio.2006.07.003","article-title":"Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.","volume":"56","author":"Fedler","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011.","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals"},{"key":"R9-20230912","first-page":"1389","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.","volume":"60","author":"Lukac","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jinf.2016.07.014","article-title":"Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis.","volume":"73","author":"Flokas","year":"2016","journal-title":"J Infect"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jhm.2157","article-title":"Impact of extended-spectrum \u03b2-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection.","volume":"9","author":"MacVane","year":"2014","journal-title":"J Hosp Med"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1542\/peds.2011-1330","article-title":"Subcommittee on Urinary Tract Infection., Steering Committee on Quality Improvement and Management. Urinary Tract Infection: clinical practice guideline for the diagnosis and management of an initial UTI in febrile infants and young children.","volume":"128","author":"Roberts","year":"2011","journal-title":"Pediatrics"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/jhm.1960","article-title":"Discordant antibiotic therapy and length of stay in children hospitalized for urinary tract infection.","volume":"7","author":"Jerardi","year":"2012","journal-title":"J Hosp Med"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"e0190910","DOI":"10.1371\/journal.pone.0190910","article-title":"Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a French prospective multicenter study.","volume":"13","author":"Madhi","year":"2018","journal-title":"PLoS One"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40265-018-0988-1","article-title":"Antibiotics and cure rates in childhood febrile urinary tract infections in clinical trials: a systematic review and meta-analysis.","volume":"78","author":"Vazouras","year":"2018","journal-title":"Drugs"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","article-title":"The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010\u20132011.","volume":"48","author":"Zykov","year":"2016","journal-title":"Infect Dis"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ped.12842","article-title":"Causative pathogens and antibiotic resistance in children hospitalized for urinary tract infection.","volume":"58","author":"Ko\u00e7ak","year":"2016","journal-title":"Pediatr Int"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"e8571","DOI":"10.1097\/MD.0000000000008571","article-title":"Community-onset extended-spectrum \u03b2-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: prevalence, risk factors, and resistances.","volume":"96","author":"P\u00e9rez Heras","year":"2017","journal-title":"Medicine"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis.","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use \u00df-lactam\/\u00df-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum \u00df-lactamase-producing bacteria?.","volume":"54","author":"Perez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/JCM.00526-12","article-title":"In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.","volume":"50","author":"Bingen","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rce.2010.03.012","article-title":"Pron\u00f3stico de las infecciones urinarias con tratamiento antibi\u00f3tico discordante.","volume":"210","author":"Ramos-Mart\u00ednez","year":"2010","journal-title":"Rev Cl\u00ednica Esp"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10096-019-03528-9","article-title":"Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriales.","volume":"38","author":"Kim","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"e20191608","DOI":"10.1542\/peds.2019-1608","article-title":"Clinical response to discordant therapy in third-generation cephalosporin-resistant UTIs.","volume":"145","author":"Wang","year":"2020","journal-title":"Pediatrics"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00467-019-04298-4","article-title":"Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children.","volume":"34","author":"Hyun","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/INF.0b013e31820d7ec4","article-title":"Outcome of urinary tract infections caused by extended spectrum \u03b2-lactamase-producing Enterobacteriaceae in children.","volume":"30","author":"Tratselas","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0974-7788.59946","article-title":"Sample size calculation.","volume":"1","author":"Bhalerao","year":"2010","journal-title":"Int J Ayurveda Res"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1128\/AAC.03974-14","article-title":"Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-\u03b2-lactamase-producing Escherichia coli.","volume":"58","author":"Tratselas","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:58:32Z","timestamp":1694559512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002838"}},"subtitle":["TOO CUTE Study"],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002838","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}